Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thibaut Barnoud

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Pharmacology & Therapeutics|June 10, 2024
Mechanistic insights into medulloblastoma relapseKendell Peterson, Maria Turos-Cabal, April D Salvador, et al.
Cancer Research|April 30, 2026
SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-XL in Clear Cell Renal Cell CarcinomaAnusha Uprety, Chandler Judd, Emily D Villella, et al.
Cancer Research|August 18, 2018
Tailoring Chemotherapy for the African-Centric S47 Variant of TP53Thibaut Barnoud, Anna Budina-Kolomets, Subhasree Basu, et al.
Nature Communications|January 26, 2020
African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxinKumar Sachin Singh, Julia I-Ju Leu, Thibaut Barnoud, et al.
Nature Communications|March 21, 2020
Author Correction: African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxinKumar Sachin Singh, Julia I-Ju Leu, Thibaut Barnoud, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2023
Common activities and predictive gene signature identified for genetic hypomorphs of <i>TP53</i>Jessica C Leung, Julia I-Ju Leu, Alexandra Indeglia, et al.
Frontiers in Molecular Biosciences|April 27, 2023
PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinomaMariana M Paz, Giulia D S Ferretti, Mafalda M C Martins-Dinis, et al.
Cancer Research Communications|July 13, 2023
The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint InhibitionDavid C Stieg, Joshua L D Parris, Tyler Hong Loong Yang, et al.
Cancer Research Communications|February 21, 2022
HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanomaJoshua L D Parris, Thibaut Barnoud, Julia I-Ju Leu, et al.
Elife|November 10, 2020
Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47SerKeerthana Gnanapradeepan, Julia I-Ju Leu, Subhasree Basu, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Pharmacology & Therapeutics|June 10, 2024
Mechanistic insights into medulloblastoma relapseKendell Peterson, Maria Turos-Cabal, April D Salvador, et al.
Cancer Research|April 30, 2026
SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-XL in Clear Cell Renal Cell CarcinomaAnusha Uprety, Chandler Judd, Emily D Villella, et al.
Cancer Research|August 18, 2018
Tailoring Chemotherapy for the African-Centric S47 Variant of TP53Thibaut Barnoud, Anna Budina-Kolomets, Subhasree Basu, et al.
Nature Communications|January 26, 2020
African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxinKumar Sachin Singh, Julia I-Ju Leu, Thibaut Barnoud, et al.
Nature Communications|March 21, 2020
Author Correction: African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxinKumar Sachin Singh, Julia I-Ju Leu, Thibaut Barnoud, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2023
Common activities and predictive gene signature identified for genetic hypomorphs of <i>TP53</i>Jessica C Leung, Julia I-Ju Leu, Alexandra Indeglia, et al.
Frontiers in Molecular Biosciences|April 27, 2023
PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinomaMariana M Paz, Giulia D S Ferretti, Mafalda M C Martins-Dinis, et al.
Cancer Research Communications|July 13, 2023
The African-centric P47S Variant of <i>TP53</i> Confers Immune Dysregulation and Impaired Response to Immune Checkpoint InhibitionDavid C Stieg, Joshua L D Parris, Tyler Hong Loong Yang, et al.
Cancer Research Communications|February 21, 2022
HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanomaJoshua L D Parris, Thibaut Barnoud, Julia I-Ju Leu, et al.
Elife|November 10, 2020
Increased mTOR activity and metabolic efficiency in mouse and human cells containing the African-centric tumor-predisposing p53 variant Pro47SerKeerthana Gnanapradeepan, Julia I-Ju Leu, Subhasree Basu, et al.
Pageof 4